Oncology
🇺🇸 FDA Page 2FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 13–24 of 246 articles
Opinion: Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise
ASCO26: Gastrointestinal Cancers Enter the Limelight Amid Key Readout Surge
AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma
FDA Flashback: Key Breast Cancer Decisions from April 2026
ASCO Preview: Akeso's Ivonescimab Under Scrutiny
Pfizer sharpens prostate cancer case with Talzenna win — oncology
Legend Biotech surges on early in vivo CAR-T data for lymphoma
AstraZeneca's Camizestrant: Navigating Divergent Regulatory Paths for Breast Cancer Treatment
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
A Brief History of Major Events in Oncology
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
FDA Approves Orally Disintegrating Nilotinib (Cavhanza) for Chronic Myeloid Leukemia